Looking to buy the report?


Anemia is the most common and persistent form of hematological abnormality found among the oncology diseased patients. Chemotherapy-induced anemia is primarily due to chemotherapy, which delays or limits the progression of treatment, and contributes significantly to both fatigue and diminished quality of life. Some of the major symptoms include mouth sores, taste changes, or nausea, which reduce the nutrients intake to develop red blood cells. A large segment of the population suffering from cancer additionally suffers from the CIA during treatment. As per the 2018 publication in Dovepress, the incidence of anemia is highest, with at least 50-60% needing a transfusion.

Report Coverage

This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases and statuses of clinical trials across major regions of the world are provided, with data obtained from multiple sources. The report also includes a list of key sponsors, having pipeline products for the concerned market.

Chemotherapy-induced Anemia Clinical Trial Analysis, by Phase and Status

  • The clinical trial analysis for chemotherapy-induced anemia, indicates that there are around XX number of trials under various phases
  • Phase X trials accounted for the majority share
  • The trial data analysis suggests a number of ongoing trials and the ones terminated

Chemotherapy-induced Anemia Clinical Trials Analysis, by Geography

  • By geography, the scope of the report covers the regional assessment for clinical trials, globally. It covers concise information of registered clinical trials, in different countries, across several developed and emerging markets
  • The driving factors for this market include technological advancement in the identification of chemotherapy-induced myelosuppression targets from different organs of the body, such as bone marrow, and blood systems, such as peripheral blood. Further, the awareness regarding CIA, its demand for early recognition, prevention, and prompt treatment are the some of the major driving factors for several small- and medium-sized, technologically-advanced companies, to compete with big players, for this market

Key Sponsors in Chemotherapy-induced Anemia Clinical Trials

The report will cover analysis on trails and information on key sponsors, companies, and researchers.

Research Methodology

Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and in-house team of research experts. The pipeline assessment reports are generated, based on the information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research are validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports are continuously updated, to incorporate the most relevant and authentic information to our clients.

Reasons to buy the Report

This report will help you understand

  • The number of clinical trials that are being conducted worldwide
  • The key products under development (Phase I, Phase II, and Phase III)
  • The main areas of research under development (by product, mechanism of action, molecule, delivery, etc.)
  • The average recruitment size in trials
  • Key deals between institutions and industries
  • Gather insights on regional and country level data
  • Review of dormant and discontinued studies across the category
  • Information on key sponsors and profiles
  • Protocol and design comparisons, to generate the best solution for your product development strategy


1. Introduction

2. Research Methodology

3. Disease Epidemiology and Trends

4. Healthcare Expenditure and R&D Trends

5. Executive Summary

6. Clinical Trials Segmentation, by Phase

                6.1 Phase-III Product Candidates

                6.2 Phase-II Product Candidates

                6.3 Phase-I Product Candidates

7. Clinical Trials, Segmentation, by Status

                7.1 Suspended

                7.2 Terminated

                7.3 Withdrawn

                7.4 Ongoing

                7.5 Completed

                7.6 Other Statuses

8. Pipeline Therapeutic Assessment (Infographic Charts and Brief description)

                8.1. By Clinical Phase and Molecule Type

                8.2. By Clinical Phase and Route of Administration

                8.3 By Sponsor/Collaborator/Institutions

                8.4 By Geography

9. Market Updates

10. Key Sponsor Profiles

11. Sources and Disclaimer

12. About Mordor Intelligence

Looking to buy the report?

Need a report that reflects how COVID-19 has impacted this market and its growth?

Looking to customize report?



By submitting, you confirm that you agree to our privacy policy